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INTRODUCTION
The control of mammalian cell cycle involves a family of
proteins that bind to and inhibit the cyclin-dependent kinas-
es (CDK) (1). Recent biochemical and genetic studies sug-
gest that these CDK inhibitors may act as tumor suppres-
sors (2). They bind to the specific CDKs or CDK-cyclin
complexes and inhibit kinase activities contributing to the
proper control of the G1-S transition, and thereby resulting
in an arrest of the cell cycle (2).
Based on the comparative studies of amino acid sequences
and biochemical properties, two classes of CDK inhibitors,
INK family and CIP/KIP family (3), have been identified
(2). The INK family includes p16, p15, and p18 (2). The
CIP/KIP family includes p21, p27, and p57, and compared
with INK family members, these inhibitors have a less selec-
tive inhibitory effect on many CDK-complexes with a main
activity during G1 phase (3).
The p21 (WAF, WAF1) is a small protein that affects the
function of most known cyclin/CDK complexes, blocking
DNA replication and cell cycle progression into S phase (3).
p21 plays a dual cell cycle inhibitory function at the G1 check-
point, by interacting with cyclin/CDK complexes and also
with the DNA polymerase  replication factor proliferating
cell nuclear antigen, binding with the targets on separate
domains and inhibiting its activity (2, 3). This pathway is
important because it allows the cell to repair DNA rather
than replicating DNA errors that may lead to a cellular trans-
formation (2). Recent studies suggest that the WAF1 gene
contain p53 binding sites and be transactivated after a treat-
ment with DNA damaging agents and that the p21 prod-
uct be a potent downstream effector of p53 tumor suppres-
sor gene function (3).
Because p21 protein is mostly expressed in actively pro-
liferating cells, but rarely in latent cells, p21 expression is
well correlated with proliferating index. p21 seems to induce
a cell cycle arrest and apoptosis in actively proliferating cells
and is an important factor regulating the cell cycle in prolif-
erating cells (4).    
Overexpression of p21 results in growth inhibition of colon
cancer cells, brain tumor cells, and leukemia cells and can
induce a growth arrest and apoptosis of human carcinoma
cell lines (1). However, the expression of p21 varies in neo-
plastic and nonneoplastic lesions of different organs and p21
performs different functions through p53-dependent or inde-
pendent pathways (4). 
Previous studies on non-Hodgkin’ s lymphomas (NHL)
showed that the p53 protein expression is a frequent find-
ing in high-grade NHL with a 27% frequency in high-grade
NHL of the mucosa-associated lymphoid tissue (MALT) type,
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Expressions of p53 and p21 in Primary Gastric Lymphomas
The p21 overexpression is thought to be a consequence of the p53 induced ac-
tivation of the p21 gene. The immunohistochemical evaluation of p53 and p21
can be a valuable means of assessing the functional status of the p53 gene
product. We examined the overexpression of p21 and p53 proteins in primary
gastric lymphomas and the correlation with prognosis. A total of 32 cases of gas-
tric lymphomas was classified into low-grade lymphomas of mucosa-associated
lymphoid tissue type (n=16) and high-grade B-cell lymphomas (n=16). In low-grade
lymphomas, only one case showed p53 positivity and all cases were p21-nega-
tive. In high-grade lymphomas, seven cases were p53+/p21- (44%), one case
was p53+/p21+ (6%), and eight cases were p53-/p21- (50%). The p53+/p21-
cases had a much lower percentage of patients sustaining a continuous com-
plete remission state (3/7, 43%) compared with other cases (6/7, 86%). From
these results, we concluded that p21 expression is rare in primary gastric lym-
phomas. Therefore, p53-positive lymphomas can be assumed as having p53
mutation. And combined studies of p53 and p21 may be used as a prognostic
indicator in primary gastric high-grade lymphomas. 
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but not in low-grade cases (5). However, there are few data
concerning the p21 expression pattern in primary gastric
lymphomas. In this study, we analyzed the expression of
p21 in primary gastric B-cell lymphomas by immunohisto-
chemical stains using a p21-specific monoclonal antibody.
MATERIALS AND METHODS
Materials
Paraffin-embedded tissue blocks from 32 cases of primary
gastric B-cell lymphomas were retrieved from the Depart-
ment of Pathology, Yonsei University College of Medicine
and Department of Diagnostic Pathology, Samsung Medical
Center, Sungkyunkwan University School of Medicine in
Korea. The diagnosis of low-grade lymphoma of the MALT
type was made based on the well-established histologic cri-
teria described by Isaacson and Norton (6). Lymphomas pre-
dominantly composed of large transformed cells were diag-
nosed as high-grade B-cell lymphomas. Their clinical data,
including modalities of treatment and outcome, were ob-
tained from hospital charts. The clinical stage was determined
according to the Luganos international classification (7).
Immunohistochemistry
Lymphoma samples were tested for p53 and p21 protein
expressions with a monoclonal antibody DO-7 (Novocastra
Laboratories Ltd, Newcastle upon Tyne, UK; dilution 1:100)
and with a monoclonal antibody EA10 (Transduction Labo-
ratories, Lexington, NY; dilution 1:100), respectively. The
immunohistochemical analysis was performed on formalin-
fixed, paraffin-embedded material. Briefly, sections were
deparaffinized in xylene, rehydrated, washed in distilled
water, immersed in 10 mM citrate buffer with pH 6, and
microwaved (twice for 5 min each). The sections were treat-
ed with a 3% H2O2 to reduce endogenous peroxidase activi-
ty, washed in phosphate-buffered saline, and were subse-
quently subjected to the primary antibody reaction. Detec-
tion of the immunoreactive staining was carried out by the
labelled streptavidin biotin method using LSAB kit (DAKO,
U.S.A.). The sections were subjected to a color reaction with
diaminobenzidine and counterstained with Mayer’ s hema-
toxylin.
Cells were considered positive only when a distinct nuclear
immunostaining could be shown, excluding cells with faint
staining. Immunostained slides were first scanned under a
low power magnification (×100) to locate the areas with max-
imal positive cells and then scored by counting the number
of positive tumor cells at ×400 or ×1,000 field. A quanti-
tative evaluation of antigen expression was performed and it
was considered as positive if more than 10% of tumor cells
were immunostained. 
Statistical analysis
Fisher’ s exact test was used to analyze the correlation be-
tween patient’ s prognosis and immunophenotype. p<0.05
was considered to be statistically significant.
RESULTS
Clinical results
Thirty-two cases of primary gastric B-cell lymphomas were
included in this study. Sixteen were low-grade gastric lym-
1 F/36 I1 Lost follow up Surgery -/-
2 M/21 II1 Complete remission Surgery + CTx 72 +/-
3 M/33 I1 Complete remission Surgery + CTx 58 +/-
4 F/74 IV Lost follow up Surgery -/-
5 F/67 II1 Lymphoma related  death Surgery + CTx 7 +/-
6 F/53 II1 Alive with disease Surgery + CTx 42 +/-
7 M/52 II1 Lymphoma related death Surgery + CTx + RTx 18 +/-
8 M/61 I2 Complete remission Surgery 32 -/-
9 F/58 II1 Complete remission Surgery + CTx 16 +/-
10 F/56 IV Complete remission Surgery + CTx 67 -/-
11 F/50 II1 Complete remission Surgery + CTx 23 -/-
12 F/56 II1 Alive with disease Surgery + CTx 42 +/-
13 F/64 II1 Alive with disease Surgery + CTx 32 -/-
14 M/40 II1 Complete remission Surgery + CTx 33 +/+
15 M/57 II1 Complete remission Surgery + CTx 34 -/-
16 M/41 I1 Complete remission Surgery 48 -/-
Table 1. Clinical characteristics and immunohistochemical results in primary gastric high-grade B-cell lymphomas
Case Sex/Age (yr) Stage Current Status Treatment Survival in months p53/p21
CTx: chemotherapy, RTx: radiotherapy, +: positive, -: negativeExpressions of p53 and p21 in Gastric Lymphomas  733
phomas of the MALT type and 16 were high-grade B-cell
lymphomas.
The median age of the patients with high-grade lympho-
mas was 51 yr, and that with low-grade MALT lymphomas
was 49 yr. In low-grade MALT lymphomas, 9 of 16 patients
presented with stage I1 disease, 6 presented with stage II1,
and 1 presented with stage II2 disease. In high-grade B-cell
lymphomas, 3 of 16 patients presented with stage I1 disease,
1 patient presented with stage I2 disease, 10 patients pre-
sented with stage II1 disease, and 2 patients presented with
stage IV disease. Mean survival duration was 38.25 and 37.43
months in low-grade and high-grade lymphomas, respective-
ly. All patients with low-grade lymphomas were alive with
no evidence of the disease. Response to treatment (defined
as achievement of complete remission) was observed in 9 of
14 (64%) high-grade cases. Five of fourteen (36%) patients
A B
Fig. 2. One case of high-grade gastric B-cell lymphoma shows that more than 10% of tumor cells are positive for p21 protein (A, ×200).
These p21-positive tumor cells are clearly demonstrated in an oil immersion view (B, ×1,000).
Fig. 3. A case of high-grade gastric B-cell lymphoma shows dif-
fuse and strong immunostaining for p53 (×200).
Fig. 1. In Peyer’ s patch section, rare p21-positive cells are found
(arrows) (×200).734 J.H. Go, W.I. Yang
showed either lymphoma-related death or partial remission
of the disease. Clinical characteristics of patients with high-
grade lymphomas were summarized in Table 1.
Immunohistochemical analyses
In Peyer’ s patch as a control, distinct nuclear immunostain-
ing for p21 was observed only in rare cells in the germinal
center, mantle and marginal zones. Most epithelial cells were
positive and could be used as a positive control (Fig. 1). 
In low-grade lymphoma group, only one case showed mod-
erate p21 staining in more than 5% of cells. Another case
was only p53-positive. The remaining 14 cases were both
p53- and p21-negative. In high-grade lymphoma group, only
one case was p21-positive (Fig. 2) and 8 of 16 cases were p53-
positive (Fig. 3). The p21-positive case was also positive for
p53. In summary, seven cases were p53+/p21-, one case was
p53+/p21+, and eight cases were p53-/p21-. Among the
five cases of high-grade lymphomas that failed to attain com-
plete remission, four cases were p53+/p21- and one case was
p53-/p21- (Table 1). 
DISCUSSION
Mutated p53 protein tends to accumulate in the cells and
thus can be detected immunohistochemically. It has been a
conventional paradigm that p53 accumulation in neoplastic
cells is synonymous with p53 mutation. Recently, however,
it was demonstrated that a large fraction of NHL cells accu-
mulate a wild type form of p53 at the nuclear level (3). The
WAF1 gene contains p53 binding sites and is transactivated
after a treatment with DNA damaging agents and the p21
product is a potent downstream effector of p53 tumor sup-
pressor gene function (1). Mutated p53 does not function as
a transcriptional regulator, and thus prevents the induction
of p53-dependent p21 synthesis (3). Previous reports
revealed that the number of neoplastic cells expressing nucle-
ar p21 was comparable to that of cells with nuclear p53
immunostaining in most p21-positive cases, and a double
marker analysis confirmed the colocalization of both p53 and
p21 in the same neoplastic cells (1). It is possible to specu-
late the p21 overexpression observed in neoplastic cells in
these cases is a consequence of the physiologic activation of
the WAF1 gene, which is the downstream target of the p53
phosphorylation (1). Overexpression of the wild type p53
protein was associated with the accumulation of p21 with
no structural abnormalities (1). Therefore the combined
immunohistochemical evaluation of p53 and p21 may be a
valuable means of assessing the functional status of the p53
tumor suppressor gene product in NHL (1).
In a reactive lymph node and infant thymus as controls,
distinct nuclear staining for p21 was observed only in rare
scattered cells (1). It has been reported that the expression of
p21 was relatively frequent (18% to 27%) in NHL (1, 3, 5).
In case of MALT or gastric lymphoma, all low-grade MALT
lymphomas were p21-negative and p53-negative (1, 5). In
our study, only 1 out of a total 16 cases of low-grade MALT
lymphomas showed p53 positivity, while all 16 cases of low-
grade MALT lymphomas were p21-negative, which is con-
sistent with the previous results. 
The previous studies revealed that p21 was expressed in
20% to 48% of high-grade gastric or MALT lymphomas
(1, 5). In our study, however, only one case showed distinct
nuclear staining in more than 10% of tumor cells. We ob-
served that many spindle cells were strongly positive for p21
in many high-grade lymphoma cases. In order to ascertain
that the reactive cells were the tumor cells, we performed a
double immunostaining for p21 and CD20 in indetermi-
nate cases. 
According to a previous study with 25 cases of high-grade
B-cell lymphomas, seven cases were p53+/p21- (28%), four
cases were p53+/p21+ (16%), one case was p53-/p21+ (4%),
and 13 cases were p53-/p21- (52%) (1). Another study with
23 cases of high-grade MALT lymphomas revealed that four
cases were p53+/p21- (17%), nine cases were p53+/p21+
(39%), two cases were p53-/p21+ (9%), and eight cases were
p53-/ p21- (35%) (5). In the present study, seven cases of
high-grade lymphomas were p53+/p21- (44%), one case
was p53+/p21+ (6%), and eight cases were p53-/p21- (50%).
In comparison with the results in previous studies, the cases
showing a p53+/p21- pattern were more frequently found
in the present study.  
Because the expression pattern of p53+/p21- means the
presence of mutated p53 gene, patients with functional p53
gene (p53+/p21+, p53-/p21-, and p53-/p21+) and those
with a p53+/p21- pattern have been considered to be differ-
ent in their treatment outcomes (1). However, these find-
ings were neither confirmed nor mentioned in the previous
studies concerning NHL, especially primary gastric lym-
phomas. In the present study, the proportion of patients in
the p53+/p21- cases who obtained a continuous complete
remission was lower (3/7, 43%) when compared with that
of the remaining ones (6/7, 86%), although this difference
was not statistically significant (p=0.266).
Although it is well established that the ability of p53 to
induce G1 arrest is related to the synthesis of the CDK inhi-
bitor p21, which promotes cell growth arrest, the mecha-
nisms by which p53 induces apoptosis are still largely un-
known (1, 3).
p21 has been implicated in the survival response of differ-
ent cells by p53-independent or p53-dependent manner, res-
cuing cells from apoptotic cell death (2, 8). In B lymphoma
cells, p53-independent elevation of p21 protein may direct-
ly interfere with the caspase cascade, thus playing a dual role
in both cell cycle progression and apoptosis. Reduction in the
induced p21 protein level results in diminished G1 arrest and
increased apoptosis in B lymphoma cells (9). In Hodgkin’ sExpressions of p53 and p21 in Gastric Lymphomas  735
lymphoma and small lymphocytic lymphoma, p27 and pos-
sibly p21 may be involved in the protection from apoptosis
(10).
In malignant lymphoma, it has been suggested that p53
induced p21-mediated growth arrest be somehow overrid-
den in NHL cells, because the cells coexpressing p21 and p53
were the actively proliferating elements (1). Alternatively, it
is possible that the expression of p21 may protect the tumor
cells from apoptosis in high-grade lymphomas. Studies involv-
ing transfection of p21 antisense oligonucleotides in prima-
ry gastric high-grade lymphomas are warranted to validate
this hypothesis. 
In conclusion, p21 expression is rare in primary gastric
lymphomas despite the high p53 positivity especially in
high-grade cases. Therefore, p53-positive cases can be con-
sidered  as having p53 mutation in primary gastric high-
grade B-cell lymphomas. In addition, the result of the com-
bined immnohistochemical evaluation of p53 and p21 may
be used as a prognostic factor in primary gastric high-grade
lymphomas, because p53+/p21- cases had lower continuous
complete remission rate than other immunophenotypes. 
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